CGC

Canopy GrowthA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$1.80

+86.1% vs current

Most likely

Base case

45%

Probability

Target price

$1.15

+18.9% vs current

B-

Bear case

25%

Probability

Target price

$0.55

-43.1% vs current

AI sentiment snapshot

Latest data as of 2026-06-17

AI commentary

News flow into June 17, 2026 is mixed but modestly improved after the June 15 earnings release: primary company materials emphasize revenue growth, lower cash burn, net cash, and an FY2027 EBITDA target, while the earlier restatement/refiling issue still caps conviction. Direct cannabis peers from the packet are more relevant than the generic biotech peer screen, but peer-level evidence and post-print analyst-revision evidence remain thin, so this stays a cautious monitoring-style setup rather than a standard-conviction rerating call.

RankAlpha Sentiment Codex - 2026-06-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventMTL integration and medical/international mix need to translate into cleaner reported marginsHigh impact

Q4 FY2026 Canada medical revenue grew 27% and international cannabis revenue grew 68%, but reported consolidated gross margin was only 12% after C$10.7M of inventory charges tied mainly to a post-acquisition inventory review; the next few quarters need to show that scale benefits can outweigh integration noise and mix pressure [#SEC-8K-2026-06-15].

2027-03-31catalystFY2027 positive Adjusted EBITDA plan is now the core rerating testHigh impact

Management said successful execution in FY2027 should drive net revenue growth, meaningful gross-margin improvement, lower operating expense, and positive Adjusted EBITDA, with improvement more pronounced in 2H FY2027 because MTL integration continues through 1H FY2027 [#SEC-8K-2026-06-15].

2027-03-31catalystNet-cash runway and financing discipline are the longer-horizon capital catalystHigh impact

Canopy ended FY2026 with C$131.3M of net cash, improved free cash outflow to C$69.1M from C$176.6M in FY2025, and framed the stronger balance sheet as expanding strategic flexibility; sustaining that runway while pursuing FY2027 EBITDA improvement would reduce financing risk, while renewed cash burn or dilution would undermine the thesis [#SEC-8K-2026-06-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-17 • Updated nightlySource: Internal modelMethodology